TESARO, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1M | $300,000 | $4.0M | — | — | — |
| Operating income | −$133.2M | −$87.1M | −$232.4M | −$167.3M | −$92.4M | −$61.9M |
| Net income | −$496.1M | −$374.2M | −$247.7M | — | — | — |
| Total assets | $862.2M | $842.3M | $255.3M | $260.4M | $135.6M | $127.4M |
| Total liabilities | $613.1M | $214.2M | $168.4M | $136.3M | $12.4M | — |
| Equity | $249.1M | $628.1M | $90.5M | $124.1M | $123.2M | $115.7M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 53.6M | 40.3M | 36.1M | 36.0M | 27.1M | 27.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −4336.0%
- Net margin
- −16144.7%
- Return on equity
- −199.2%
- Return on assets
- −57.5%
- Return on capital (ROCE)
- −19.1%
- Liabilities / assets
- 71.1%
- Debt / equity
- 2.46×
- Book value / share
- $4.64
- Revenue growth (YoY)
- 924.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- -1.44distress
- Accruals / assets
- −11.1%clean
- Beneish M-Score
- 5.51elevated
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2019-05-17A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- Phase 3Active Not Recruitingreadout ~2024-10-31A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- Phase 1Active Not Recruitingreadout ~2026-05-18Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
- Phase 3Active Not Recruitingreadout ~2026-11-26A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
- Phase 1Active Not Recruitingreadout ~2027-03-01A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Debt acceleration / triggering event · Other material eventJan 24, 2019
- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 22, 2019
- Other material eventDec 4, 2018
- Entered a material agreement · Other material eventDec 3, 2018
- Results of operationsNov 1, 2018
- Regulation FD disclosureSep 5, 2018
- Results of operationsAug 2, 2018
- Completed an acquisition or dispositionJul 18, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2019
- SC 13G/AFeb 13, 2019
- SC 13G/AFeb 12, 2019
- SC 13G/AFeb 11, 2019
- SC 13G/AFeb 6, 2019
- 15-12BFeb 1, 2019
- SC 13G/AFeb 1, 2019
- SC 13D/ANEW ENTERPRISE ASSOC. 13, LP - TESARO, INC. -- SCHEDULE 13D/A (#5E)Jan 30, 2019
- 4PRIMARY DOCUMENTJan 24, 2019
- 8-KJan 24, 2019
- POSASRJan 22, 2019
- S-8 POSJan 22, 2019
- S-8 POSJan 22, 2019
- S-8 POSJan 22, 2019
- S-8 POSJan 22, 2019
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.